These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35745873)

  • 1. Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature.
    Aves KL; Janitzek CM; Fougeroux CE; Theander TG; Sander AF
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Purification of Tag/Catcher AP205-Based Capsid Virus-Like Particle Vaccines.
    Aves KL; Sander AF
    Methods Mol Biol; 2024; 2720():127-141. PubMed ID: 37775662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved
    Martinez FG; Zielke RA; Fougeroux CE; Li L; Sander AF; Sikora AE
    Infect Immun; 2023 Dec; 91(12):e0024523. PubMed ID: 37916806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.
    Geeraedts F; Saluja V; ter Veer W; Amorij JP; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
    AAPS J; 2010 Jun; 12(2):215-22. PubMed ID: 20195930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.
    Fredsgaard L; Goksøyr L; Thrane S; Aves KL; Theander TG; Sander AF
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34063871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Freeze-Drying Formulations Increased the Adenovirus and Poxvirus Vaccine Storage Times and Antigen Stabilities.
    Chen Y; Liao Q; Chen T; Zhang Y; Yuan W; Xu J; Zhang X
    Virol Sin; 2021 Jun; 36(3):365-372. PubMed ID: 32696399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.
    Flood A; Estrada M; McAdams D; Ji Y; Chen D
    PLoS One; 2016; 11(11):e0164692. PubMed ID: 27851765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Studies on Stabilization of AAV Vector Formulations by Lyophilization.
    Rieser R; Menzen T; Biel M; Michalakis S; Winter G
    J Pharm Sci; 2022 Aug; 111(8):2288-2298. PubMed ID: 35259349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines.
    Aves KL; Goksøyr L; Sander AF
    Viruses; 2020 Feb; 12(2):. PubMed ID: 32041299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Efficacy of a Capsid Virus-like Particle-Based Vaccine Targeting IL-1β for Treatment of Allergic Contact Dermatitis.
    Goksøyr L; Funch AB; Okholm AK; Theander TG; de Jongh WA; Bonefeld CM; Sander AF
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of virus-like particles of red-spotted grouper nervous necrosis virus in the aqueous state, and the vaccine potential of lyophilized particles.
    Lan NT; Kim HJ; Han HJ; Lee DC; Kang BK; Han SY; Moon H; Kim HJ
    Biologicals; 2018 Jan; 51():25-31. PubMed ID: 29174141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice.
    Kang H; Martinez MR; Aves KL; Okholm AK; Wan H; Chabot S; Malik T; Sander AF; Daniels R
    iScience; 2024 Jun; 27(6):110038. PubMed ID: 38883830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of collapse lyophilized influenza vaccine formulations.
    Anamur C; Winter G; Engert J
    Int J Pharm; 2015 Apr; 483(1-2):131-41. PubMed ID: 25660049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.
    Shin WJ; Hara D; Gbormittah F; Chang H; Chang BS; Jung JU
    mBio; 2018 Nov; 9(6):. PubMed ID: 30482835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of stable influenza vaccine powder formulations: challenges and possibilities.
    Amorij JP; Huckriede A; Wilschut J; Frijlink HW; Hinrichs WL
    Pharm Res; 2008 Jun; 25(6):1256-73. PubMed ID: 18338241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.
    Lovalenti PM; Anderl J; Yee L; Nguyen V; Ghavami B; Ohtake S; Saxena A; Voss T; Truong-Le V
    Pharm Res; 2016 May; 33(5):1144-60. PubMed ID: 26818839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different temperatures.
    Thakkar SG; Ruwona TB; Williams RO; Cui Z
    Hum Vaccin Immunother; 2017 Apr; 13(4):936-946. PubMed ID: 28051903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lyophilized yeast powder for adjuvant free thermostable vaccine delivery.
    Kumar R; Kharbikar BN
    Appl Microbiol Biotechnol; 2021 Apr; 105(8):3131-3143. PubMed ID: 33834253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fundamentals of freeze-drying.
    Nail SL; Jiang S; Chongprasert S; Knopp SA
    Pharm Biotechnol; 2002; 14():281-360. PubMed ID: 12189727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
    Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
    J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.